Market Overview

Laidlaw & Co. Downgrades Intercept Pharmaceuticals to Hold, Raises Price Target to $95

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for ICPT

DateFirmActionFromTo
Sep 2018Roth CapitalInitiates Coverage OnBuy
Aug 2018RBC CapitalDowngradesOutperformSector Perform
Aug 2018Goldman SachsUpgradesSellBuy

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings

Posted-In: News Downgrades Analyst Ratings

 

Related Articles (ICPT)

Apple Reaches $1-Trillion Valuation: Jim Cramer Shares 10 Takeaways

US Unemployment Drops Back Below 4%, Nonfarm Payroll Falls Far Short Of Expectations